CG Oncology (CGON) Gets Initiated With a Buy at Guggenheim

CG Oncology, Inc. (NASDAQ:CGON) is one of the best healthcare stocks with the highest upside. On October 7, CG Oncology, Inc. (NASDAQ:CGON) was initiated with a Buy rating by Guggenheim analyst Brad Canino, who assigned the stock a $90 price target.

The firm told investors in a research note that it sees the company “rising to the top of quality oncology ideas.” It added that the non-muscle invasive bladder cancer market holds considerable pricing power and a number of patients, supporting the optimistic rating for CG Oncology, Inc. (NASDAQ:CGON).

Canino also cited CG Oncology, Inc.’s (NASDAQ:CGON) cretostimogene, which would enter FDA review in 2026, as a notable factor, highlighting its “best-in-class” efficacy and safety durability.

CG Oncology, Inc. (NASDAQ:CGON) is a clinical biopharmaceutical company that develops and commercializes bladder-sparing therapeutics for bladder cancer. Its product cretostimogene is initially in clinical development for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). The company is making significant advancements across its pipeline to develop a potential backbone bladder-sparing therapy for NMIBC. With a strong tolerability profile and safety, cretostimogene has the potential to induce a durable, complete response in bladder cancer patients.

While we acknowledge the potential of CGON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.